Component
Direct mass-spectrometric measurement of cyclooxygenase-1 acetylation in platelets
Direct mass-spectrometric measurement of cyclooxygenase-1 acetylation in platelets. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Although ibuprofen, naproxen and celecoxib all had the potential to compete with aspirin for access to the substrate binding channel of cyclooxygenase-1 in vitro, measuring aspirin target engagement directly by mass spectrometry after a single therapeutic dose of each followed by 325 milligrams of aspirin revealed a potent drug-drug interaction between ibuprofen and aspirin and between naproxen and aspirin but not between celecoxib and aspirin.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/aspirin-research/25385584.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b2de8f18887f336c8c735f7ffbd1b72b92e5da43aa6388c229590dea120439f2", "start_char": 0, "end_char": 1242, "text_sha256": "b2de8f18887f336c8c735f7ffbd1b72b92e5da43aa6388c229590dea120439f2"}
- experimental_model
- Mass-spectrometric assay of cyclooxygenase-1 acetylation in platelets from volunteers given an NSAID followed by aspirin
- exposure
- A single therapeutic dose of ibuprofen, naproxen or celecoxib followed by 325 milligrams of aspirin
- limitations
- Measures target engagement directly rather than inferring it from platelet function, and separates the drugs. A single dose of each, in volunteers rather than patients.
- nutrient_topic
- Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. · Aspirin / acetylsalicylic acid
- organism
- Human
- plain_language
- Ibuprofen and naproxen block aspirin in people; celecoxib does not.
- primary_references
- [asa-p25385584] Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. (2014). https://pubmed.ncbi.nlm.nih.gov/25385584/ DOI: 10.1073/pnas.1406997111
- tissue_or_cell_type
- Platelets
- trigger_kind
- biomarker_context Imported condition classification; unverified.
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Mass-spectrometric assay of cyclooxygenase-1 acetylation in platelets from volunteers given an NSAID followed by aspirin · source_derived_draft · unverified_draft
### asa-which-nsaids-interact Although ibuprofen, naproxen and celecoxib all had the potential to compete with aspirin for access to the substrate binding channel of cyclooxygenase-1 in vitro, measuring aspirin target engagement directly by mass spectrometry after a single therapeutic dose of each followed by 325 milligrams of aspirin revealed a potent drug-drug interaction between ibuprofen and aspirin and between naproxen and aspirin but not between celecoxib and aspirin. Condition category: biomarker_context nutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. plain_language: Ibuprofen and naproxen block aspirin in people; celecoxib does not. organism: Human tissue_or_cell_type: Platelets experimental_model: Mass-spectrometric assay of cyclooxygenase-1 acetylation in platelets from volunteers given an NSAID followed by aspirin limitations: Measures target engagement directly rather than inferring it from platelet function, and separates the drugs. A single dose of each, in volunteers rather than patients. exposure: A single therapeutic dose of ibuprofen, naproxen or celecoxib followed by 325 milligrams of aspirin evidence_span: {"source_cache": "artifacts/aspirin-research/25385584.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "b2de8f18887f336c8c735f7ffbd1b72b92e5da43aa6388c229590dea120439f2", "start_char": 0, "end_char": 1242, "text_sha256": "b2de8f18887f336c8c735f7ffbd1b72b92e5da43aa6388c229590dea120439f2"} [asa-p25385584] Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. (2014). https://pubmed.ncbi.nlm.nih.gov/25385584/ DOI: 10.1073/pnas.1406997111
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.